Type I and III interferons are good markers to monitor COVID-19 pathophysiology

[1]  H. Bluyssen,et al.  Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy , 2022, Frontiers in Immunology.

[2]  M. Diamond,et al.  Innate immunity: the first line of defense against SARS-CoV-2 , 2022, Nature Immunology.

[3]  I. Zanoni.  Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19? , 2021, Current Opinion in Virology.

[4]  Chen Liu,et al.  Potential role of IFN-α in COVID-19 patients and its underlying treatment options , 2021, Applied Microbiology and Biotechnology.

[5]  K. Akarid,et al.  The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? , 2021, Microbial Pathogenesis.

[6]  M. Yoneyama,et al.  Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors , 2021, Cellular & Molecular Immunology.

[7]  O. Silakari,et al.  The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options , 2020, Microbial Pathogenesis.

[8]  X. Montagutelli,et al.  Host genetic susceptibility to viral infections: the role of type I interferon induction , 2020, Genes & Immunity.

[9]  Dave Singh,et al.  Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial , 2020, The Lancet Respiratory Medicine.

[10]  T. Kanneganti,et al.  Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines , 2020, Trends in Immunology.

[11]  G. Schreiber.  The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 , 2020, Frontiers in Immunology.

[12]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[13]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[14]  M. Triggiani,et al.  COVID 19: a clue from innate immunity , 2020, Immunologic research.

[15]  Akiko Iwasaki,et al.  Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19 , 2020, Cell Host & Microbe.

[16]  K. Brengel-Pesce,et al.  Type I IFN immunoprofiling in COVID-19 patients , 2020, Journal of Allergy and Clinical Immunology.

[17]  L. Prokunina-Olsson,et al.  COVID-19 and emerging viral infections: The case for interferon lambda , 2020, The Journal of experimental medicine.

[18]  A. Davis,et al.  Diagnosis and Treatment of Adults With Community-Acquired Pneumonia. , 2020, JAMA.

[19]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[20]  S. Hur,et al.  Regulation of cGAS- and RLR-mediated immunity to nucleic acids , 2019, Nature Immunology.

[21]  M. Fine,et al.  Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America , 2019, American journal of respiratory and critical care medicine.

[22]  M. Diamond,et al.  Shared and Distinct Functions of Type I and Type III Interferons. , 2019, Immunity.

[23]  Zhijian J. Chen,et al.  Detection of Microbial Infections Through Innate Immune Sensing of Nucleic Acids. , 2018, Annual review of microbiology.

[24]  M. Katze,et al.  Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection , 2015, mBio.

[25]  J. Grainger.  The Virus , 1940, Nature.